204 related articles for article (PubMed ID: 24004141)
1. Survival in patients with glioblastoma receiving valganciclovir.
Söderberg-Nauclér C; Rahbar A; Stragliotto G
N Engl J Med; 2013 Sep; 369(10):985-6. PubMed ID: 24004141
[No Abstract] [Full Text] [Related]
2. The legend of cytomegalovirus and glioblastoma lives on.
Weller M; Soffietti R; Brada M
Neuro Oncol; 2014 Jan; 16(1):166. PubMed ID: 24311642
[No Abstract] [Full Text] [Related]
3. Does valganciclovir have a role in glioblastoma therapy?
Cobbs CS
Neuro Oncol; 2014 Mar; 16(3):330-1. PubMed ID: 24523453
[No Abstract] [Full Text] [Related]
4. Controversies in neuro-oncology: does valganciclovir have a role in the treatment of high-grade gliomas?
Wen PY
Neuro Oncol; 2014 Mar; 16(3):329. PubMed ID: 24523452
[No Abstract] [Full Text] [Related]
5. Valganciclovir in patients with glioblastoma.
Hellstrand K; Martner A; Bergström T
N Engl J Med; 2013 Nov; 369(21):2066. PubMed ID: 24256397
[No Abstract] [Full Text] [Related]
6. Valganciclovir in patients with glioblastoma.
Söderberg-Nauclér C; Peredo I; Stragliotto G
N Engl J Med; 2013 Nov; 369(21):2066-7. PubMed ID: 24256396
[No Abstract] [Full Text] [Related]
7. Challenging cytomegalovirus data in glioblastoma.
Wick W; Wick A; Platten M
Neuro Oncol; 2014 Jan; 16(1):165. PubMed ID: 24353326
[No Abstract] [Full Text] [Related]
8. CMV infection and glioma, a highly controversial concept struggling in the clinical arena.
Wick W; Platten M
Neuro Oncol; 2014 Mar; 16(3):332-3. PubMed ID: 24523454
[No Abstract] [Full Text] [Related]
9. Effects of valganciclovir as an add-on therapy in patients with cytomegalovirus-positive glioblastoma: a randomized, double-blind, hypothesis-generating study.
Stragliotto G; Rahbar A; Solberg NW; Lilja A; Taher C; Orrego A; Bjurman B; Tammik C; Skarman P; Peredo I; Söderberg-Nauclér C
Int J Cancer; 2013 Sep; 133(5):1204-13. PubMed ID: 23404447
[TBL] [Abstract][Full Text] [Related]
10. [Inconclusive data].
Kinhult S; Werlenius K; Hallbeck AL; Nyström PW; Männikkö V; Johansson M
Lakartidningen; 2014 Jul 2-15; 111(27-28):1192. PubMed ID: 25162111
[No Abstract] [Full Text] [Related]
11. [Questionable effect of antiviral therapy in malignant brain tumors].
Kinhult S; Werlenius K; Hallbeck AL; Nyström PW; Männikkö V; Johansson M
Lakartidningen; 2014 Apr 29-May 13; 111(18-19):809. PubMed ID: 24855749
[No Abstract] [Full Text] [Related]
12. Good maths is needed to understand CMV data in glioblastoma.
Wick W; Wick A; Platten M
Int J Cancer; 2014 Jun; 134(12):2991-2. PubMed ID: 24248554
[No Abstract] [Full Text] [Related]
13. Cytomegalovirus and glioblastoma: a review of evidence for their association and indications for testing and treatment.
Solomon IH; Ramkissoon SH; Milner DA; Folkerth RD
J Neuropathol Exp Neurol; 2014 Nov; 73(11):994-8. PubMed ID: 25289896
[TBL] [Abstract][Full Text] [Related]
14. Immortal time bias in retrospective analysis: is there a survival benefit in patients with glioblastoma who received prolonged treatment of adjuvant valganciclovir?
Liu CJ; Hu YW
Int J Cancer; 2014 Jul; 135(1):250-1. PubMed ID: 24338590
[No Abstract] [Full Text] [Related]
15. Use of Cox regression with treatment status as a time-dependent covariate to re-analyze survival benefit excludes immortal time bias effect in patients with glioblastoma who received prolonged adjuvant treatment with valganciclovir.
Söderberg-Naucler C; Peredo I; Rahbar A; Hansson F; Nordlund A; Stragliotto G
Int J Cancer; 2014 Jul; 135(1):248-9. PubMed ID: 24338548
[No Abstract] [Full Text] [Related]
16. Effective treatment of experimental glioblastoma by HSV vector-mediated TNF alpha and HSV-tk gene transfer in combination with radiosurgery and ganciclovir administration.
Niranjan A; Moriuchi S; Lunsford LD; Kondziolka D; Flickinger JC; Fellows W; Rajendiran S; Tamura M; Cohen JB; Glorioso JC
Mol Ther; 2000 Aug; 2(2):114-20. PubMed ID: 10947938
[TBL] [Abstract][Full Text] [Related]
17. Editorial commentary: Use of valganciclovir for prevention and treatment of cytomegalovirus disease.
Snydman DR
Clin Infect Dis; 2008 Jan; 46(1):28-9. PubMed ID: 18171209
[No Abstract] [Full Text] [Related]
18. Neurosurgical management and prognosis of patients with glioblastoma that progresses during bevacizumab treatment.
Clark AJ; Lamborn KR; Butowski NA; Chang SM; Prados MD; Clarke JL; McDermott MW; Parsa AT; Berger MS; Aghi MK
Neurosurgery; 2012 Feb; 70(2):361-70. PubMed ID: 21841523
[TBL] [Abstract][Full Text] [Related]
19. Valganciclovir as treatment for cytomegalovirus disease in solid organ transplant recipients.
Len O; Gavaldà J; Aguado JM; Borrell N; Cervera C; Cisneros JM; Cuervas-Mons V; Gurguí M; Martin-Dávila P; Montejo M; Muñoz P; Bou G; Carratalà J; Torre-Cisneros J; Pahissa A;
Clin Infect Dis; 2008 Jan; 46(1):20-7. PubMed ID: 18171208
[TBL] [Abstract][Full Text] [Related]
20. Incidence, risk factors, and outcome of cytomegalovirus infection and disease in patients receiving prophylaxis with oral valganciclovir or intravenous ganciclovir after umbilical cord blood transplantation.
Montesinos P; Sanz J; Cantero S; Lorenzo I; Martín G; Saavedra S; Palau J; Romero M; Montava A; Senent L; Martínez J; Jarque I; Salavert M; Córdoba J; Gómez L; Weiss S; Moscardó F; de la Rubia J; Larrea L; Sanz MA; Sanz GF
Biol Blood Marrow Transplant; 2009 Jun; 15(6):730-40. PubMed ID: 19450758
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
